Siemens debuts RT plan platform

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

ANAHEIM, CALIF.-Siemens Healthcare unveiled the IM-Real ART Solution, a real-time planning system that produces images in 10 minutes or less, at the 2009 American Association of Physicists in Medicine meeting.

ANAHEIM, CALIF.-Siemens Healthcare unveiled the IM-Real ART Solution, a real-time planning system that produces images in 10 minutes or less, at the 2009 American Association of Physicists in Medicine meeting.

IM-RealART Solution accounts for the difference in the patient from scan to scan, while still maintaining the same timeslots, according to the company.

The platform is designed specifically for immediate replanning within Image-Guided Radiation Therapy (IGRT) and can be combined with Siemens' CTVision and PROWESS RealART system for in-room imaging.

Other products displayed at AAPM included Syngo MultiModality Workplace (formerly known as Leonardo), Syngo RT Therapist 4.1, Syngo RT Oncologist, and MVision for volumetric, inline, and target imaging.

Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
1 expert is featured in this series.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Related Content